АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ ПОСЛЕ ЧРЕСКОЖНОГО КОРОНАРНОГО ВМЕШАТЕЛЬСТВА. ОБЗОР ЛИТЕРАТУРЫ.
Введение. Обзор посвящен вопросам антитромботических комбинаций у пациентов с фибрилляцией предсердий (ФП), перенесших чрескожное коронарное вмешательство (ЧКВ) и стентирование. Цель. Анализ основной литературы и клинических рекомендаций об эффективности и безопасности антитромботических комбинаций у пациентов с ФП, перенесших ЧКВ и стентирование. Стратегия поиска. Проведен поиск научных публикаций в поисковых системах PubMed, Web of Science, Google Scholar, в электронных научных библиотеках eLibrary, СyberLeninka. Глубина поиска 15 лет (2006-2021). Поиск информации об эффективности и безопасности антитромботических комбинаций у пациентов с ФП, перенесших ЧКВ и стентирование. Результаты. В настоящее время проводятся очень много исследовании, в которых сравнивают применение оральных антикоагулянтов (ОАК) у пациентов с ФП после ЧКВ. С появлением результатов крупных рандомизированных исследований рекомендации по антитромботической терапии у данной категории пациентов обновились. Мы стремимся проанализировать имеющуюся в настоящее время литературу, посвященную проблеме ТАТ и ДАТ у пациентов с ФП и острым коронарным синдромом (ОКС), и предоставить данные о рисках и преимуществах. Выводы. Обзор современной литературы по антитромботической терапии у пациентов с ФП, перенесших ЧКВ и последующее стентирование коронарных артерий, показывает, что предпочтительной схемой является двойная антитромботическая терапия (ДАТ), состоящая из ингибитора P2Y12 в сочетании с ОАК, а тройная антитромботическая терапия (ТАТ) подвергает их повышенному риску кровотечения. Решения относительно конкретных агентов и продолжительности лечения должны основываться на тромботическом риске, риске кровотечения и предпочтениях пациента.
Асель А. Касымова1, https://orcid.org/0000-0001-9333-4146 Джамиля А. Мансурова1, https://orcid.org/0000-0003-2439-2056 Людмила К. Каражанова1, http://orcid.org/0000-0002-4719-6034 Айсулу С. Жунуспекова1, https://orcid.org/0000-0002-2413-317X 1 НАО «Медицинский университет Семей», Кафедра кардиологии и интервенционной аритмологии, г. Семей, Республика Казахстан.
1. Ako J., Okumura K., Nakao K. et al. Dual anti-thrombotic therapy with dabigatran after percutaneous coronary intervention in atrial fibrillation: Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI trial // Circulation Journal. 2019;83(2):327-333. doi:10.1253/circj.CJ-18-0874 2. Alexander J.H., Wojdyla D., Vora A.N. et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients with Atrial Fibrillation Early and Late after an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from augustus // Circulation. Published online 2020. 1618-1627. doi:10.1161/CIRCULATIONAHA.120.046534 3. Angiolillo D.J., Goodman S.G., Bhatt D.L. et al. Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update // Circulation: Cardiovascular Interventions. 2016. 9(11). doi:10.1161/CIRCINTERVENTIONS.116.004395 4. Bonello L., Tantry U.S., Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate // Journal of the American College of Cardiology. 2010. Vol 56, 919-933. doi:10.1016/j.jacc.2010.04.047 5. Cannon C.P., Bhatt D.L., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation // New England Journal of Medicine. 2017. 377(16):1513-1524. doi:10.1056/nejmoa1708454 6. Cannon C.P., Gropper S., Bhatt D.L. et al. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting // Clinical Cardiology. 2016. 39(10):555-564. doi:10.1002/clc.22572 7. Castini D., Persampieri S., Sabatelli L. et al. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome // Heart and Vessels. 2019. 34(10):1621-1630. doi:10.1007/s00380-019-01405-1 8. Collet J.P., Thiele H., Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation // European Heart Journal. 2021. 42(14):1289-1367. doi:10.1093/eurheartj/ehaa575 9. Coppens M., Synhorst D., Eikelboom J.W., Yusuf S., Shestakovska O., Connolly S.J. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: Results from the AVERROES trial // European Heart Journal. 2014. 35(28):1856-1863. doi:10.1093/eurheartj/ehu048 10. Desai A., Escamilla-Ocanas C., Dilip D., Saber H., Damani R. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic // The Journal of Stroke and Cerebrovascular Diseases. 2021. 30(4). doi:10.1016/j.jstrokecerebrovasdis.2021.105654 11. Dewilde W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial // The Lancet. 2013. 381(9872):1107-1115. doi:10.1016/S0140-6736(12)62177-1 12. Fosbol E.L., Wang T.Y., Li S. et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy // American Heart Journal. 2013. 166(5):864-870. doi:10.1016/j.ahj.2013.08.005 13. Gibson C.M., Mehran R., Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI // New England Journal of Medicine. 2016. 375(25):2423-2434. doi:10.1056/nejmoa1611594 14. Gimbel M., Qaderdan K., Willemsen L. et al. Articles Clopidogrel versus Ticagrelor or Prasugrel in Patients Aged 70 Years or Older with Non-ST-Elevation Acute Coronary Syndrome (POPular AGE): The Randomised, Open-Label, Non-Inferiority Trial. Vol 395. Lancet. 2020 Apr 25;395(10233):1374-1381.doi: 10.1016/S0140-6736(20)30325-1. 15. Gimbel M.E., Tavenier A.H., Bor W. et al. Ticagrelor versus clopidogrel in older patients with nste-acs using oral anticoagulation: A sub-analysis of the popular age trial // Journal of Clinical Medicine. 2020. 9(10):1-9. doi:10.3390/jcm9103249 16. Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation // New England Journal of Medicine. 2013. 369(22):2093-2104. doi:10.1056/nejmoa1310907 17. González-Pacheco H., Márquez M.F., Arias-Mendoza A. et al. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation // Journal of Cardiology. 2015. 66(2):148-154. doi:10.1016/j.jjcc.2014.11.001 18. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation // New England Journal of Medicine. 2011. 365(11):981-992. doi:10.1056/nejmoa1107039 19. Heger L.A., Danzer M., Bode C. et al. Dual-Pathway Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in Stable Coronary Artery Disease: A Single-Center, Single-Operator, Retrospective Cohort Study // Frontiers in Medicine. 2020. 7. doi:10.3389/fmed.2020.00414 20. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) // European Heart Journal. 2021. 42(5):373-498. doi:10.1093/eurheartj/ehaa612 21. Hulot J.S., Bura A., Villard E., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects // Blood. 2006. 108(7):2244-2247. doi:10.1182/blood-2006-04-013052 22. Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation // European Heart Journal. 2018. 39(2):119-177. doi:10.1093/eurheartj/ehx393 23. Kang J., Kim H.S. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: Focus on unique feature of east Asian and “Asian paradox” // Korean Circulation Journal. 2018. 48(7):537-551. doi:10.4070/kcj.2018.0166 24. Kralev S., Schneider K., Lang S., Süselbeck T., Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography // PLoS ONE. 2011;6(9). doi:10.1371/journal.pone.0024964 25. Kwon S., Jung J.H., Choi E.K. et al. Impact of non-Vitamin K antagonist oral anticoagulants on the change of antithrombotic regimens in patients with atrial fibrillation undergoing percutaneous coronary intervention // Korean Circulation Journal. 2021. 51(5):409-422. doi:10.4070/KCJ.2020.0407 26. Lamberts M., Gislason G.H., Olesen J.B. et al. Oral Anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention // J Am Coll Cardiol. 2013. 62(11):981-989. doi:10.1016/j.jacc.2013.05.029 27. Lee K., Yoo S.Y., Suh J. et al. Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated inhibition of platelet aggregation, inflammation and myonecrosis by adjunctive cilostazol loading in patients with acute coronary syndrome) study // International Journal of Cardiology. 2015. 190:370-375. doi:10.1016/j.ijcard.2015.04.180 28. Levine G.N., Jeong Y.H., Goto S., et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI // Nature Reviews Cardiology. 2014. 11(10):597-606. doi:10.1038/nrcardio.2014.104 29. Lip G.Yh., Collet J.P., Haude M. et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the Europ // Europace. 2019;21(2):192-193. doi:10.1093/europace/euy174 30. Lopes R.D., Heizer G., Aronson R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation // New England Journal of Medicine. 2019. 380(16):1509-1524. doi:10.1056/nejmoa1817083 31. Lopes R.D., Heizer G., Aronson R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation // New England Journal of Medicine. 2019. 380(16):1509-1524. doi:10.1056/nejmoa1817083 32. Lopes R.D., Hong H., Alexander J.H. Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: Finding the sweet spot // European Heart Journal. 2019. 40(46):3768-3770. doi:10.1093/eurheartj/ehz823 33. Mihajlovi M., Marinkovi M., Kozie M., aMujovi N., Lip G.Yh., Potpara T.S. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention // Kardiologia Polska. 2020. 78(6):512-519. doi:10.33963/KP.15428 34. Neumann F.J., Sechtem U., Banning A.P., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes // European Heart Journal. 2020. 41(3):407-477. doi:10.1093/eurheartj/ehz425 35. Neumann F.J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization // European Heart Journal. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394 36. Oldgren J., Steg P.G., Hohnloser S.H. et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: A subgroup analysis from the RE-DUAL PCI trial // European Heart Journal. 2019. 40(19):1553-1562. doi:10.1093/eurheartj/ehz059 37. Pereira N.L., Farkouh M.E., So D. et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes after Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial // JAMA - Journal of the American Medical Association. 2020. 324(8):761-771. doi:10.1001/jama.2020.12443 38. Potpara T.S., Mujovic N., Proietti M. et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: Meta-analysis of pooled data from the Pioneer AF-PCI, RE-DUAL PCI, and augustus trials // Europace. 2020. 22(1):33-46. doi:10.1093/europace/euz259 39. Qaderdan K., Ishak M., Heestermans A.A. et al. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older - Rationale and design of the POPular AGE study // American Heart Journal. 2015. 170(5):981-985.e1. doi:10.1016/j.ahj.2015.07.030 40. Shen A.Y., Yao J.F., Brar S.S., Jorgensen M.B., Chen W. Racia. Ethnic Differences in the Risk of Intracranial Hemorrhage Among Patients With Atrial Fibrillation // J Am Coll Cardiol. 2007. 50(4):309-315. doi:10.1016/j.jacc.2007.01.098 41. Sherwood M.W., Cyr D.D., Jones W.S. et al. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial // JACC: Cardiovascular Interventions. 2016. 9(16):1694-1702. doi:10.1016/J.JCIN.2016.05.039 42. Soliman E.Z., Safford M.M., Muntner P., et al. Atrial fibrillation and the risk of myocardial infarction // JAMA Internal Medicine. 2014. 174(1). doi:10.1001/jamainternmed.2013.11912 43. Staudacher D.L., Kaiser M., Hehrlein C., Bode C., Ahrens I., Merx M.W. Triple antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with indication for oral anticoagulation: Data from a single center registry // PLoS ONE. 2015;10(10). doi:10.1371/journal.pone.0140101 44. Sun Y., Lu Q., Tao X., Cheng B., Yang G. Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis // Frontiers in Genetics. 2020. 11. doi:10.3389/fgene.2020.576046 45. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS // European Heart Journal. 2018. 39(3):213-254. doi:10.1093/eurheartj/ehx419 46. Van Rein N., Heide-Jørgensen U., Lijfering W.M., Dekkers O.M., Sørensen H.T., Cannegieter S.C. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy // Circulation. 2019;139(6):775-786. doi:10.1161/CIRCULATIONAHA.118.036248 47. Verlinden N.J., Coons J.C., Iasella C.J., Kane-Gill S.L. Triple Antithrombotic Therapy with Aspirin, P2Y12 Inhibitor, and Warfarin after Percutaneous Coronary Intervention // Journal of Cardiovascular Pharmacology and Therapeutics. 2017. 22(6):546-551. doi:10.1177/1074248417698042 48. Vranckx P., Valgimigli M., Eckardt L. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial // The Lancet. 2019. 394(10206):1335-1343. doi:10.1016/S0140-6736(19)31872-0 49. Wang W., Shao C., Xu B. et al. CYP2C19 genotype has prognostic value in specific populations following coronary stenting // Annals of Translational Medicine. 2021. 9(13):1066-1066. doi:10.21037/atm-20-7724 50. Xie X., Ma Y.T., Yang Y.N. et al. CYP2C19 Phenotype, Stent Thrombosis, Myocardial Infarction, and Mortality in Patients with Coronary Stent Placement in a Chinese Population // PLoS ONE. 2013. 8(3). doi:10.1371/journal.pone.0059344 51. Yang X., Xu S., Chi G., et al. Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update // Front Cardiovasc Med. 2021. 8:660986. doi:10.3389/fcvm.2021.660986 52. Yasuda S, Kaikita K., Akao M. et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease // New England Journal of Medicine. 2019. 381(12):1103-1113. doi:10.1056/nejmoa1904143
Количество просмотров: 224

Ключевые слова:

Библиографическая ссылка

Касымова А.А., Мансурова Д. А., Каражанова Л.К., Жунуспекова А.С. Антитромботическая терапия у пациентов с фибрилляцией предсердий с острым коронарным синдромом после чрескожного коронарного вмешательства. Обзор литературы // Наука и Здравоохранение. 2022. 6(Т.24). С. 143-151. doi 10.34689/SH.2022.24.6.019

Авторизируйтесь для отправки комментариев